Proliferative characteristics of Philadelphia‐negative myeloproliferative neoplasms ‐ clinical implications

Šefer, Dragan; Bižić-Radulović, Sandra; Kraguljac-Kurtovic, Nada; Bogdanović, Andrija; Čokić, Vladan P.; Miljić, Predrag; Beleslin-Čokić, Bojana B.; Knezevic, Vesna; Ajtić, Olivera Mitrović; Leković, Danijela; Gotić, Mirjana

doi:10.1111/ijlh.12564

Int J Lab Hematology

2016

DOI: 10.1111/ijlh.12564

|View full text |Cite

Proliferative characteristics of Philadelphia‐negative myeloproliferative neoplasms ‐ clinical implications

Dragan Šefer

Sandra Bižić-Radulović

Nada Kraguljac-Kurtovic

et al.

Abstract: Exploration of the PB proliferative characteristics of Ph MPN on diagnosis may be helpful in revealing early-prefibrotic PMF. Monitoring the levels of circulating CD34 cells may provide a sensitive indicator of fibrotic evolution in PV and PMF.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 35 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Treatment of primary myelofibrosis: Where we stand today?

Bogdanović,

Leković

2024

Srpski medicinski časopis Lekarske komore

View full text Add to dashboard Cite

Introduction: Primary myelofibrosis (PMF) is a clonal hematopoietic neoplastic disease characterized by constitutive complaints, splenomegaly, anemia and very often thrombocytopenia. Aim: To analyze and compare data from clinical trials, focusing on both current and emerging therapeutics. Methods: The analysis of published clinical trials and relevant papers. Results: Currently, the gold standard for treating primary myelofibrosis (PMF) is ruxolitinib, the first-in-class JAK inhibitor (JAKi). It has achieved a ≥35% reduction in spleen volume (SVR) in 41.9% of patients compared to placebo and has led to a >50% improvement in symptoms, as measured by the Total Symptom Score (TSS), in 49.5% of treated individuals. Ruxolitinib is not an ideal drug, as some patients experience worsening anemia, thrombocytopenia, and an increased susceptibility to various infections. Some patients are required to discontinue the treatment or reduce the dosage. Another approved JAK inhibitor, fedratinib, has shown promising results as a second-line treatment following ruxolitinib failure. As a first-line therapy, fedratinib achieved a spleen volume reduction (SVR) of ≥35% in 47% of patients, with a >50% improvement in TSS in 40% of cases. In transfusion-dependent patients, momelotinib has demonstrated good results, showing non-inferiority to ruxolitinib, with similar spleen volume reduction (SVR≥35%) rates of 26.5% compared to 29% with ruxolitinib. Momelotinib treatment reduced transfusion independence by 17% compared to ruxolitinib (66% vs 49%). In thrombocytopenic patients (Plt 50-100 x109 /L), pacritinib is the newest therapy; it reduces spleen volume compared to adjusted ruxolitinib dosing without worsening thrombocytopenia. Drugs combined with ruxolitinib (e.g. navitoklaks, pelabresib) have the purpose to improve the outcome, especially in spleen reduction. Conclusion: Treating PMF remains a challenge. While ruxolitinib provides effective disease control in nearly half of patients, new therapies are needed to enhance outcomes both overall and in those with refractory disease.

show abstract

Treatment of primary myelofibrosis: Where we stand today?

Bogdanović,

Leković

2024

Srpski medicinski časopis Lekarske komore

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Proliferative characteristics of Philadelphia‐negative myeloproliferative neoplasms ‐ clinical implications

Abstract: Exploration of the PB proliferative characteristics of Ph MPN on diagnosis may be helpful in revealing early-prefibrotic PMF. Monitoring the levels of circulating CD34 cells may provide a sensitive indicator of fibrotic evolution in PV and PMF.

Cited by 1 publication

References 35 publications

Treatment of primary myelofibrosis: Where we stand today?

Treatment of primary myelofibrosis: Where we stand today?

Contact Info

Product

Resources

About